New option listings for October 22nd include GRISTONE BIO, INC. (GRTSQ). Option delistings effective October 22nd include POWERSCHOOL HOLDINGS ...

Gritstone bio shares are trading lower by 65% during Thursday's session. The company announced it voluntarily filed for Chapter 11 restructuring.

Gritstone Oncology ( (GRTS) ) has shared an update. Gritstone bio, Inc., a biotech firm specializing in potent vaccines, has voluntarily filed for Chapter 11 bankruptcy to restructure and preserve ...

Gritstone Oncology (GRTS – Research Report) received a Hold rating and price target from JMP Securities analyst Roy Buchanan yesterday. The company’s shares closed yesterday at $0.58.

Gritstone Bio files for Chapter 11 bankruptcy, aims to preserve value and continue with clinical programs despite stock ...

Fintel reports that on October 2, 2024, B. Riley Securities downgraded their outlook for Gritstone bio (NasdaqGS:GRTS) from Buy to Neutral. Analyst Price Forecast Suggests 1,880.58% Upside As of ...

Leaders of Gritstone Bio Inc. could read the writing on the wall: Financial times for drug developers are tough and the ...

Gritstone bio (NASDAQ:GRTS) stock cratered 50% Tuesday, the day after the cancer vaccine developer reported data for its GRANITE immunotherapy and said it had retained a financial advisor to ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

One of Gritstone’s flagship projects is GRANITE, a neoantigen immunotherapy that has recently reported encouraging interim Phase 2 data. This program, along with others in their pipeline, reflects ...

Gritstone Oncology ( (GRTS) ) has shared an update. Gritstone bio, Inc., a biotech firm specializing in potent vaccines, has ...